GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (NAS:TNDM) » Definitions » Beneish M-Score
中文

Tandem Diabetes Care (Tandem Diabetes Care) Beneish M-Score : -2.83 (As of Apr. 25, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Tandem Diabetes Care Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.83 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Tandem Diabetes Care's Beneish M-Score or its related term are showing as below:

TNDM' s Beneish M-Score Range Over the Past 10 Years
Min: -3.79   Med: -2.73   Max: 0.14
Current: -2.83

During the past 13 years, the highest Beneish M-Score of Tandem Diabetes Care was 0.14. The lowest was -3.79. And the median was -2.73.


Tandem Diabetes Care Beneish M-Score Historical Data

The historical data trend for Tandem Diabetes Care's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tandem Diabetes Care Beneish M-Score Chart

Tandem Diabetes Care Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.71 -1.48 -2.55 -2.75 -2.83

Tandem Diabetes Care Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.75 -3.07 -3.14 -3.33 -2.83

Competitive Comparison of Tandem Diabetes Care's Beneish M-Score

For the Medical Devices subindustry, Tandem Diabetes Care's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tandem Diabetes Care's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's Beneish M-Score falls into.



Tandem Diabetes Care Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Tandem Diabetes Care for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.986+0.528 * 1.0482+0.404 * 1.8863+0.892 * 0.9332+0.115 * 0.8484
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1252+4.679 * -0.122061-0.327 * 1.1473
=-2.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $105.6 Mil.
Revenue was 196.796 + 185.622 + 195.917 + 169.383 = $747.7 Mil.
Gross Profit was 93.295 + 89.753 + 101.735 + 82.907 = $367.7 Mil.
Total Current Assets was $748.0 Mil.
Total Assets was $952.7 Mil.
Property, Plant and Equipment(Net PPE) was $164.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $15.7 Mil.
Selling, General, & Admin. Expense(SGA) was $352.5 Mil.
Total Current Liabilities was $195.3 Mil.
Long-Term Debt & Capital Lease Obligation was $398.6 Mil.
Net Income was -30.002 + -32.961 + -35.775 + -123.873 = $-222.6 Mil.
Non Operating Income was 0 + 0 + 0 + -74.519 = $-74.5 Mil.
Cash Flow from Operations was -7.216 + 0.055 + -6.323 + -18.326 = $-31.8 Mil.
Total Receivables was $114.7 Mil.
Revenue was 220.501 + 204.547 + 200.262 + 175.907 = $801.2 Mil.
Gross Profit was 115.522 + 104.425 + 101.946 + 91.093 = $413.0 Mil.
Total Current Assets was $850.0 Mil.
Total Assets was $1,052.8 Mil.
Property, Plant and Equipment(Net PPE) was $179.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $14.3 Mil.
Selling, General, & Admin. Expense(SGA) was $335.7 Mil.
Total Current Liabilities was $165.3 Mil.
Long-Term Debt & Capital Lease Obligation was $406.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(105.555 / 747.718) / (114.717 / 801.217)
=0.14117 / 0.143178
=0.986

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(412.986 / 801.217) / (367.69 / 747.718)
=0.515448 / 0.49175
=1.0482

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (747.989 + 164.333) / 952.658) / (1 - (849.976 + 179.178) / 1052.785)
=0.04234 / 0.022446
=1.8863

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=747.718 / 801.217
=0.9332

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(14.33 / (14.33 + 179.178)) / (15.715 / (15.715 + 164.333))
=0.074054 / 0.087282
=0.8484

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(352.503 / 747.718) / (335.681 / 801.217)
=0.471438 / 0.418964
=1.1252

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((398.607 + 195.258) / 952.658) / ((406.756 + 165.29) / 1052.785)
=0.623377 / 0.543365
=1.1473

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-222.611 - -74.519 - -31.81) / 952.658
=-0.122061

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Tandem Diabetes Care has a M-score of -2.83 suggests that the company is unlikely to be a manipulator.


Tandem Diabetes Care Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Tandem Diabetes Care's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Tandem Diabetes Care (Tandem Diabetes Care) Business Description

Traded in Other Exchanges
Address
11075 Roselle Street, San Diego, CA, USA, 92121
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Executives
Dick Allen director 11045 ROSELLE STREET, SAN DIEGO CA 92121
Shannon Marie Hansen officer: SVP & General Counsel C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Leigh Vosseller officer: Senior Vice President and CFO C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kathleen Mcgroddy-goetz director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Peyton R Howell director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
David B Berger officer: GENERAL COUNSEL 11045 ROSELLE STREET, SAN DIEGO CA 92121
Malagueira Joao Paulo Falcao director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Myoungil Cha director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kim D Blickenstaff director, officer: PRESIDENT AND CEO C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
John F Sheridan officer: EXECUTIVE VP AND COO C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
Christopher J Twomey director 4767 NEXUS CENTRE DRIVE, SAN DIEGO CA 92121
Rebecca B Robertson director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
James Leal officer: SVP, Operations C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Elizabeth Anne Gasser officer: EVP, Chief Strategy Officer C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Susan Morrison officer: CAO 11045 ROSELLE STREET, SAN DIEGO CA 92121

Tandem Diabetes Care (Tandem Diabetes Care) Headlines

From GuruFocus